An injection pen of Zepbound, Eli Lilly’s weight reduction drug, is displayed in New York Metropolis, U.S., December 11, 2023.
Brendan McDermid | Reuters
Eli Lilly on Tuesday reported fourth-quarter income and adjusted earnings that topped expectations on the sturdy launch of its new weight reduction drug, Zepbound, and better costs for its blockbuster diabetes remedy, Mounjaro.
Zepbound, which gained approval from U.S. regulators in early November, raked in $175.8 million in gross sales for the fourth quarter.
The quarterly outcomes are the primary to incorporate gross sales of Zepbound, which some analysts say may submit greater than a billion {dollars} in gross sales in its first yr available on the market and finally, change into the most important drug of all time.
Here is what Eli Lilly reported for the fourth quarter in contrast with what Wall Avenue was anticipating, based mostly on a survey of analysts by LSEG, previously often known as Refinitiv:
- Earnings per share: $2.49 adjusted vs. $2.22 anticipated
- Income: $9.35 billion vs. $8.93 billion anticipated
Eli Lilly posted internet revenue of $2.19 billion, or $2.42 a share, for the fourth quarter. That compares with a revenue of $1.94 billion, or $2.14 a share, a yr earlier.
Excluding one-time gadgets related to the worth of intangible belongings, amongst different changes, the corporate posted a per-share revenue of $2.49 for the fourth quarter of 2023.
The pharmaceutical large booked fourth-quarter income of $9.35 billion, up 28% from the identical interval a yr in the past.
Eli Lilly additionally issued its full-year forecast for 2024, which was usually in step with expectations.
The corporate expects full-year adjusted earnings of $12.20 to $12.70 per share. Eli Lilly additionally forecast 2024 income of $40.4 billion to $41.6 billion.
Analysts surveyed by LSEG anticipated full-year adjusted earnings of $12.43 per share and gross sales of $39.38 billion.
Shares of Eli Lilly jumped virtually 60% final yr as weight reduction medicine skyrocketed in recognition regardless of hefty value tags, combined insurance coverage protection, a handful of disagreeable unwanted effects and provide shortages. With a market cap of roughly $673 billion, Eli Lilly is the most important pharmaceutical firm based mostly within the U.S.
Mounjaro sees larger demand, costs
Eli Lilly expects demand for its incretin medicine – therapies reminiscent of Zepbound and Mounjaro that concentrate on hormones produced within the intestine – to outpace provide in 2024, the corporate’s chief monetary officer, Anat Ashkenazi, mentioned throughout an earnings name Tuesday.
However Ashkenazi mentioned the corporate achieved its objective of doubling capability for producing incretin medicine by the tip of 2023. She added that Eli Lilly’s capability enlargement efforts will proceed with “equal urgency,” with essentially the most important manufacturing will increase occurring within the second half of the yr.
By that time within the yr, Ashkenazi mentioned the corporate expects its manufacturing of sellable doses of incretin medicine to be at the very least 1.5 occasions the manufacturing of these doses within the second half of final yr.
Larger costs for older medicine, significantly Mounjaro, helped drive up Eli Lilly’s income, the corporate mentioned. Mounjaro booked $2.21 billion in gross sales for the fourth quarter, up from simply $279.2 million in the identical interval a yr in the past.
Analysts had anticipated the drug to usher in $1.73 billion in worldwide gross sales, in accordance with estimates compiled by FactSet.
That enhance displays heightened demand but additionally “larger realized costs” within the U.S. as a result of decreased use of Eli Lilly’s financial savings card packages as entry to the drug continued to broaden through the quarter, the corporate mentioned. The financial savings card packages purpose to assist decrease the out-of-pocket prices for medicine like Mounjaro for sufferers.
Outcomes from throughout the portfolio
Income development was additionally pushed by gross sales of Eli Lilly’s breast most cancers tablet Verzenio, which rose 42% to $1.15 billion for the quarter as a result of elevated demand and better costs.
That consequence got here in beneath analysts’ expectations, nonetheless, which known as for $1.18 billion in gross sales for the interval.
Gross sales of Jardiance, a pill that lowers blood sugar in Kind 2 diabetes sufferers, climbed 30% to $798.1 million for the fourth quarter. Analysts had anticipated $771.8 million in gross sales from Jardiance.
Jardiance, which Eli Lilly shares with Boehringer Ingelheim, is among the many first 10 medicine chosen to face value negotiations with the federal Medicare program. These value talks heated up final week after Medicare despatched its preliminary value affords for every drug to the producers.
In the meantime, Eli Lilly mentioned larger costs had been offset by decrease costs of its different diabetes medication Trulicity and insulin product Humalog.
Trulicity reported $1.67 billion in income, down 14% from the identical interval a yr in the past. Analysts had anticipated Trulicity to get $1.77 billion in gross sales for the quarter.
Humalog noticed $366.6 million in income for the quarter, down 33% from the year-ago interval. Analysts had anticipated the drugs to e book $438 million in gross sales, in accordance with FactSet.
That lower is no surprise: Final yr, Eli Lilly mentioned it could reduce costs of Humalog and one other generally prescribed insulin by 70% and cap month-to-month out-of-pocket prices at $35 at sure retail pharmacies for individuals who have personal insurance coverage beginning Could 1, 2023.
Throughout an earnings name, Eli Lilly reiterated that it expects an FDA’s determination on Eli Lilly’s experimental Alzheimer’s drug, donanemab, within the first quarter of the yr. That remedy considerably slowed the development of the memory-robbing illness in sufferers on the early levels of it.
Do not miss these tales from CNBC PRO:
